Abstract 218P
Background
Adjuvant chemotherapy improved disease-free survival (DFS) among MIUC patients (pts). CheckMate 274 study demonstrated adjuvant immunotherapy improved DFS in MIUC pts. However, few studies explored the efficacy of adjuvant chemotherapy plus immunotherapy in MIUC pts. Our real-world study aimed to evaluate the effectiveness of adjuvant chemoimmunotherapy versus chemotherapy in high-risk MIUC pts.
Methods
Clinical data of high-risk MIUC pts between October 2016 and March 2023 were retrospectively collected from Sun Yat-sen University Cancer Center. After radical surgery, pT3/4 and pN+ MIUC pts without prior neoadjuvant therapy received adjuvant tislelizumab combined with GC (T+GC) or GC. In T+GC group, pts firstly received cisplatin 70 mg/m2 D2, and gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks for 2-6 cycles, then received tislelizumab 200 mg every 3 weeks for 2-17 cycles. In GC group, pts received cisplatin 70 mg/m2 D2, and gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks for 2-6 cycles. The primary outcome was DFS, and secondary outcomes were OS and safety.
Results
The median follow-up was 17.7(2.1-38.3) months, totally 117 MIUC pts were analyzed, with a median age of 64 (34-85) years. 75.2% were male, 46.2% were UTUC, 20.5% were variant histology; pT3=58.9%, pT4=17.1%; pN+=52.1%. In T+GC group (n=68), the mean number of tislelizumab cycles was 4 and GC cycles was 2.7. In GC group (n=49), the mean number of GC cycles was 2.9. The T+GC group (n=68) had a significantly longer DFS compared with the GC group (n=49) (median DFS (95% CI): 19.1 (6.0-32.5) vs 8.4 (1.0-39.4) months, HR=0.172, P<0.001). While lymphovascular invasion pts had a lower probability of DFS (HR=22.1 (2.8-173.5), P=0.003). The OS was longer in the T+GC group (n=68) (median OS (95% CI): 20.1(6.0-32.5) vs 12.2(1.5-39.4) months, P=0.186). Longer follow-up was required to determine the OS benefits in T+GC group. Grade 1-2 immune related adverse events including pruritus (n=10), ALT/AST increased (n=8), hyperthyroidism (n=5) and hyperglycaemia (n=3).
Conclusions
Our data demonstrated effectiveness of tislelizumab combined with GC as adjuvant therapy for pT3/4 and pN+ MIUC pts in real world.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract